ישראל - עברית - Ministry of Health

abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 150 mg - lacosamide

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 200 mg - lacosamide

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 50 mg - lacosamide

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 100 mg - lacosamide

ישראל - עברית - Ministry of Health

novartis israel ltd - brolucizumab - תמיסה להזרקה - brolucizumab 120 mg / 1 ml - brolucizumab

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

ישראל - עברית - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - תרחיף - perampanel as anhydrous 0.5 mg / 1 ml - perampanel

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.